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Summary The distribution of tissue plasminogen activator (t-PA) has been studied in a series of 38 human
brain tumours and two specimens of cerebral cortex, using the monoclonal antibody ESP6. t-PA was localised
in vascular endothelium in the majority of tumours and both the cortical specimens, confirmed by double
staining with Ulex europaeus lectin (Uel) and Factor 8-related antigen. Nineteen out of 22 high grade
astrocytomas showed strong endothelial staining whereas staining was weak or absent in the four low grade
astrocytomas studied. No consistent relationship was found between the pattern of staining and tumour grade
in the other tumours, although strong staining of the three metastatic lesions with Uel was observed. Among
the astroglial tumours only one glioblastoma showed any tumour cell staining for t-PA, which raises
questions concerning the origin of t-PA producing cells derived from human gliomas in vitro. Studies of t-PA
in brain tumours should take account of this vascular localisation before concluding that the activity is
derived from neoplastic cells.
Studies of the behaviour of human gliomas in vitro have
consistently shown the emergence of two main cell types: one
expressing glial fibrillary acidic protein (GFAP) but not
fibronectin (FN), and the other expressing FN but not
GFAP (Lolait et al., 1983; Franks & Burrow, 1986;
McKeever et al., 1987; Paetau, 1988). The latter cell type has
been considered by some to be a less differentiated neoplastic
glial cell whose growth is enhanced by culture, a view
apparently strengthened by the observation that its growth
pattern is aberrant and not contact-inhibited (Kennedy et al.,
1987; Frame et al., 1984). A contrary view holds that these
cells are not of parenchymal origin but instead derive from
mesenchymal or endothelial elements responding to growth
factors produced by the tumours (Manoury, 1977; Franks &
Burrow, 1986; Jacobsen et al., 1987; McKeever et al., 1987;
Rutka et al., 1987). The finding that similar growth proper-
ties and antigen expression can be observed in endothelial
cells derived from non-neoplastic tissues (Laug et al., 1980;
McAuslan et al., 1980) supports this latter view.
Plasminogen activator (PA) production has been linked
with phenotypic transformation in vitro and thus malignancy
(Mullins & Rohrlich, 1983). In in vitro studies of cells
derived from human gliomas the expression of PA has been
used as evidence for a neoplastic and indeed malignant or
less differentiated state and such expression has been found
to correlate inversely with expression of glial characteristics
(Frame et al., 1984; McLean et al., 1986).
Two distinct groups of PA are recognised: urokinase (so
called because of its presence in urine) and tissue associated
(t-PA), which has been isolated from a variety of normal and
abnormal tissues. t-PA has been isolated from placental bed,
vascular endothelium, tumour tissue and transformed or
malignant cells in vitro (Reddy & Kline, 1980; Mullins &
Rorhlich, 1983). Tissue activity was localised histochemically
to vascular endothelium nearly 30 years ago (Todd, 1959),
then to the endothelium of normal brain vessels (Takashima
et al., 1969), and more recently has been immunohisto-
chemically identified in the blood vessels of the eye (Tripathi
et al., 1987). Kohga and colleagues (Kohga et al., 1985)
compared t-PA with urokinase in colonic cancer and found
the former in stroma and vessel endothelium and the latter
in tumour cells. The distribution of t-PA in brain tumours
appears not to have been studied in detail.
Although many tumour cells produce urokinase in vitro
(Reddy & Kline, 1980; Rijken & Collen, 1981) PA activity in
cultures from brain tumours has been shown to be distinct
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from urokinase (Tucker et al., 1978). PA derived from wet
tissue has often been assayed by fibrinolytic activity without
further characterisation (Quindlen & Bucher, 1987) and the
exact source of t-PA in intact tumour tissue is uncertain. The
problem is further compounded by the finding that discre-
pancies may occur between the type of activator found in
solid tumour tissue and that synthesised by cells cultured
from the same tumour (Markus et al., 1984).
In an attempt to determine whether t-PA producing cells
in cultures from human gliomas could be derived from the
tumour parenchyma or the stroma we have studied the
localisation of t-PA in sections of brain tumours using a
monoclonal antibody (ESP6, Bioscot, Edinburgh) that recog-
nises cell-associated t-PA.
Materials and methods
The tissue examined in this study derived from diagnostic
biopsy specimens received in the Neuropathology Labora-
tory, University of Leeds and consisted of four low grade
astrocytomas (including one gemistocytic astrocytoma), 22
malignant astrocytomas, (20 grade 4 and two grade 3), three
meningiomas, three metastases, two pieces of cortex (one
normal and one from the vicinity of a malignant astro-
cytoma), two choroid plexus papillomas, one ependymoma,
one ganglioglioma, one oligodendroglioma and one astro-
blastoma.
Fresh tissue was frozen in isopentane or directly in liquid
nitrogen. After storage periods ranging from 36h to 3 years
8pm cryostat sections were cut, mounted on poly-L-lysine
coated glass slides, air dried overnight and fixed for 15min
in acetone.
After pre-treatment with normal goat serum (NGS)
diluted 1:5 in Tris buffered saline (TBS) to block non-
specific binding site sections were stained for 1 h with the
monoclonal antibody ESP6 (Bioscot, Edinburgh), which
recognises cell-associated t-PA but not urokinase, diluted 1:2
in NGS (diluted 1:20 in TBS) followed by a goat anti-mouse
fluorescein conjugate diluted 1:50 in NGS (diluted 1:20 in
TBS). Double staining was then carried out with a rabbit
anti-human polyclonal antibody against one or more of the
following: glial fibrillary acidic protein (GFAP) (Dakopatts;
dilution 1:200 in TBS) for all astroglial lesions; Factor 8
related antigen (F8-Rag) (Dakopatts; diluted 1:100 in TBS)
or fibronectin (FN) (Dakopatts; diluted 1:200 in TBS). The
second antibody was applied for 30min, followed by a swine
anti-rabbit rhodamine conjugate (diluted 1:50 in TBS) for
30min. Sections were also double stained with Ulex euro-
paeus lectin conjugated with FITC (diluted 1:50 in phos-
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phate buffer) although for these the t-PA was demonstrated
with a rhodamine rather than a fluorescein conjugate.
Sections from all tumours were stained with ESP6 and F8-
Rag, and ESP6 and Uel; sections from the astrocytic
tumours were also stained with ESP6 and fibronectin, and
ESP6 and GFAP. The final preparations were viewed under
fluorescent light using mean exciting wavelengths of 490nm
and 540nm for fluorescein and rhodamine respectively.
Sections of full-term placental bed were used as positive
controls for t-PA, Uel and F8-Rag, and a glioblastoma
provided positive control for FN and GFAP. Specificity of
Uel staining was checked by co-incubation with a 0.1 M
solution of alpha-L(-) fucose which bound the lectin and
abolished positive staining in test and control sections.
To assess the specificity of the antibody to t-PA protein
extraction was carried out from one gram of glioblastoma
multiforme tissue and after SDS gel electrophoresis, with
standard molecular weight markers for comparison, nitro-
cellulose blots (Towbin et al., 1979) were stained with a three
layer immunoperoxidase method with final visualisation by
4-chloro-naphthol.
Results
The nitrocellulose blot demonstrated four bands of reactivity
(Figure 1): a very faint one at 72kD, a defined band at
55 kD, and two less defined bands centred on 41 and 31 kD.
Control sections from placenta stained for t-PA showed
variable staining of villous trophoblast, consistent staining of
extravillous trophoblast and patchy staining of the vascular
endothelium. In contrast only the endothelium showed
staining for F8-Rag or with Uel (which was abolished by
prior incubation with fucose).
Uel, F8-Rag, GFAP and FN staining
Uel positivity was restricted to endothelium in all cases
except the three metastases (see below) which showed strong
staining of the cell surface of the majority of tumour cells,
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Figure 1 Western blot of protein extract from glioblastoma
multiforme (left) showing bands at 55 kD, 41 kD and 31 kD. See
text for interpretation.
and two meningiomas which showed focal positive tumour
cell staining.
F8-Rag staining was entirely restricted to the surface and
cytoplasm of vascular endothelium.
All the high and low grade astrocytomas showed uniform
positive staining for GFAP of cell processes and, to a lesser
extent, cell bodies. FN was limited to vascular or peri-
vascular stromal elements and no staining of tumour cell
surfaces was seen on any of the tumours.
t-PA staining
In all the tumours examined t-PA was clearly localised in
vascular endothelium (identified by co-expression of F8-Rag
or FN, or Uel staining) although the intensity of staining
varied from case to case and with tumour type. The staining
was of a granular or punctuate appearance, distributed
largely within the cell cytoplasm although some surface
activity was also resolvable (Figure 2).
Astrocytic tumours and cerebral cortex In 17 grade 4 and
both grade 3 astrocytomas vascular staining for t-PA was
strong and uniform (Figure 3) and particularly easy to see in
the hyperplastic endothelial cells that are characteristic of
these tumours; in two grade 4 astrocytomas strongly and
weakly stained vessels co-existed, and in one grade 4 tumour
only occasional vessels stained. These findings in high grade
tumours contrasted with the four low grade astrocytomas in
which staining was absent in three (Figure 4) and only barely
detectable in the gemistocytic lesion. Staining of tumour cells
(co-expressing GFAP) was only found in one grade 4
astrocytoma (Figure 5) which was characterised by plentiful
giant cells. In the cortical specimen adjacent to a grade 3
astrocytoma the majority of vessels stained strongly although
they were not obviously hyperplastic; in contrast the speci-
men of normal cortex showed generally very weak staining
in numerous small vessels although stronger reaction could
be detected in the few larger vessels.
Other gliomas Uniform strong vessel staining for t-PA was
seen in the ganglioglioma and one choroid plexus papilloma;
mixed strong and weak vessel staining was seen in the
astroblastoma, the ependymoma and one choroid plexus
papilloma; the oligodendroglioma showed uniformly weak
reaction. In one choroid plexus papilloma and the oligo-
dendroglioma scattered single cells showed strong positive
staining; in the oligodendroglioma these cells were restricted
to an area in which macrophages were present, and in the
choroid plexus papilloma the pattern of staining also sug-
gested non-tumour cells were reacting.
Meningiomas Two of these showed no reaction for t-PA
and one showed a few faintly stained vessels. This latter
lesion also showed focal staining of tumour cells around
psammoma bodies.
Metastases Two showed strong endothelial staining for
t-PA although in one (an adenocarcinoma) the vessels showed
little Uel positivity; a similarly weak vascular reaction for
Uel was seen in the third tumour (completely anaplastic)
with very weak staining for t-PA. By contrast tumour cells
in all three showed strong uniform surface staining with Uel
but no t-PA reaction.
Discussion
The monoclonal antibody used in this study was raised
against human melanoma t-PA which has a MW of -72,000
(Rijken & Collen, 1981) and appears to be similar to, if not
identical with, uterine t-PA, which itself appears to be closely
related to vessel-associated PA (Rijken et al., 1980; Ogston,
1983). Although estimates of the molecular weight of t-PA
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Figure 2 Blood vessel in glioblastoma multiforme showing t-PA Figure 3 Photomicrographs of the same field showing a cluster
reactivity in endothelium (ESP6 monoclonal antibody with fluor- of proliferating blood vessels in a glioblastoma multiforme
escein) distinct from GFAP staining of surrounding tumour staining with Uel (left, photographed at 540nm for fluorescein)
(polyclonal anti-GFAP antibody with rhodamine). t-PA staining and anti-t-PA (right, ESP6 monoclonal antibody, photographed
is largely cytoplasmic. Double exposure at 490nm and 540nm. at 490nm for rhodamine). Note exact correspondence of the two
Bar=30pm. staining patterns which show restriction of reactivity to
endothelial cells. Bar=30pm.
Figure 4 Photomicrographs of the same field showing a thin
walled blood vessel from a low grade cerebral astrocytoma.
There is defined staining of the endothelium with Uel (left,
photographed at 540nm for fluorescein) but no corresponding
staining for t-PA (right, ESP6 monoclonal antibody, photo-
graphed at 490nm for rhodamine). This contrasts with the
finding in most malignant astrocytic tumours (see Figures 2 and
3). Bar=30gpm.
1981) and 68,000 for human uterine t-PA (Rijken et al.,
1979) other estimates have yielded values in the range 52,500
(for pig heart) to 80,000 (for human cadaveric vascular trees)
(Reddy & Kline, 1980). There is, however, general agreement
that the molecule is separable into two subunits with mole-
cular weights variously estimated at 33,000 and 39,000
(Rijken & Collen, 1981) or 31,000 and 38,000 (Rijken et al.,
1979). In the present study it would seem from the nitro-
cellulose blot that under the conditions of extraction used
the majority of t-PA in the sample glioblastoma was in the
form of two subunits with molecular weights 41,000 and
31,000, corresponding to previous published findings and a
parent molecular weight of 72,000. The weakness of the
reaction at 72,000 would be in keeping with this interpre-
tation. The nature of the substance reacting at 55,000 is not
clear; although its molecular weight would be consistent with
its being t-PA, further studies would be needed to confirm
this.
This study shows minimal tumour cell positivity for t-PA
in a wide range of human nervous system lesions, which is in
sharp contrast to the predominant localisation in endo-
thelium. The pattern of cellular distribution also differs, with
granular/punctuate positivity in endothelium and uniform
Figure 5 Giant cell glioblastoma multiforme showing focal t-PA
reactivity which is predominantly on cell surfaces. ESP6 mono-
clonal antibody, photographed at 540nm for rhodamine.
Bar=30gm.
surface reactivity in the few parenchymal cells that reacted.
These observations are consistent with some of the activity
being lysosomal in endothelial cells as has been found in
other species and tissues (Ali & Lack, 1965), and the finding
that in vitro tumour cell PA is membrane associated (Quigley
et al., 1976).
The fact that only one grade 4 astrocytoma showed
tumour cell positivity may reflect the production of cell-
associated t-PA in a form not recognised by the antibody
used, or may indicate that the bulk of activity measurable in
wet tissue is in fact derived from vascular endothelium. The
staining of cells that could have been macrophages in two
tumours would accord with the observation that, with
appropriate stimulation, PA activity can be induced
(Unkeless et al., 1974) although the number of such cells
that express t-PA is small when compared to the numbers
found with more specific macrophage markers (unpublished
observations).
The finding that t-PA is largely localised in the endo-
thelium of malignant gliomas and some non-malignant
tumours is not totally unexpected but it highlights the
danger of interpreting in vitro results without knowledge of
tissue localisation. From these results it will be apparent thatbiochemical studies of t-PA levels in tumour specimens will
have to take account of tumour vascularity or else demon-
strate clearly that the t-PA under study is not localised in
vessels.
Whether the form of t-PA observed in this study has a
role in nervous system tumour cell invasion is questionable.
Identification of other immunologically distinct PAs, such as
those studied in colonic carcinomas (Kohga et al., 1985),
might reveal secretion by tumour parenchymal cells in
gliomas. The finding that t-PA was present in brain vessels
adjacent to tumour indicates that its production is an
intrinsic property of endothelium which is enhanced when it
is stimulated to proliferate by tumour angiogenesis factors.
A purified fibroblast growth factor-like substance derived
from a human hepatoma cell line has recently been shown to
promote angiogenesis in vivo and induce PA activity,
enhance DNA synthesis and promote motility in confluent
bovine endothelial cells (Presta et al., 1986). Lymphokines
have also been shown to have a similar inductive effect on
endothelium (Tiku & Tomasi, 1985). These observations
provide support for the view that the phenotypically trans-
formed t-PA and FN producing cells derived in vitro from
human malignant gliomas are of vascular origin and are
responding to factors produced by neoplastic glial cells
(Manoury, 1977; Franks & Burrow, 1986; Jacobsen et al.,
1987; McKeever et al., 1987; Rutka et al., 1987). Clearly a
broader study of endothelium in other sites (neoplastic,
reactive and normal) and the response of cultured cells to
glioma-derived factors would be of interest.
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The consistent failure of the vessels of low grade astro-
cytomas to show t-PA activity raises the possibility that this
phenomenon could be utilised in grading of these tumours,
although this would clearly need examination of larger
numbers of cases and of intermediate forms.
Vascularity of malignant gliomas, and in particular aber-
rant vascular proliferation, has been found to correlate with
a poorer prognosis (Cohadon et al., 1985; Fulling & Garcia,
1985) and there might be profit in attempting to correlate
t-PA activity with outcome.
Although this study did not set out to examine the value
of Uel reactivity in the diagnosis of tumours, the pattern
observed in the three metastases is of interest in the light of
the observation that staining of breast carcinomas with Uel
correlates with outcome (Fenlon et al., 1987). The possible
value of Uel staining in the diagnosis of central nervous
system metastases and their distinction from anaplastic
gliomas might repay further study using both cryostat
sections and paraffin processed tissue.
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